In a strategic move set to reshape the landscape of cardioendocrine drug development, clinical-stage biopharmaceutical firm Lisata Therapeutics has announced its acquisition of Marea Therapeutics. The merger aims to consolidate the companies’ resources to advance a suite of first-in-class, next-generation medicines designed to address significant unmet needs in patients with complex cardiovascular and endocrine conditions.
Concurrent with the acquisition, Lisata successfully finalized a private placement financing of Series C non-voting convertible preferred stock. The financing round, which was significantly oversubscribed, is expected to generate approximately $225 million in gross proceeds. These funds are earmarked for accelerating the development of Marea’s promising pipeline of antibody-based therapeutics.
Marea’s portfolio, which forms the cornerstone of the deal, is headlined by MAR001, a candidate currently undergoing Phase IIb clinical trials for the treatment of severe hypertriglyceridemia. Additionally, the company has developed MAR005, a half-life-extended iteration of the drug that is nearing Phase III development. Also in the company’s clinical arsenal is MAR002, which is being investigated in a Phase II trial for patients suffering from acromegaly.
“After a thorough review of strategic alternatives, the Marea acquisition marks a significant milestone,” said Dr. David Mazzo, CEO of Lisata. “Marea’s product candidate portfolio addresses significant unmet need across a range of cardioendocrine diseases. This pipeline is designed to overcome the limitations of current treatment paradigms and has the potential to establish a new standard of care.”
As part of the leadership restructuring accompanying the merger, Dr. Josh Lehrer, formerly the CEO of Marea, will join the Lisata executive team as Chief Operating Officer and President. “Joining with Lisata gives our first-in-class antibody programs a faster path to patients who today have limited options,” Dr. Lehrer noted, expressing gratitude for the strong support from both new and legacy investors.
The acquisition is backed by a powerhouse group of life sciences investors, including RA Capital Management, Forbion, Third Rock Ventures, Alpha Wave, Perceptive Advisors, and Sofinnova Investments, among others. The robust participation from these firms underscores widespread market confidence in the therapeutic potential of the combined entity’s clinical assets.
Looking ahead, the company has established a clear roadmap for its expanded clinical trials. Stakeholders and the medical community can expect significant updates, with topline data from the ongoing studies of MAR001, MAR005, and MAR002 projected for release by the fourth quarter of 2027. By integrating Marea’s specialized antibody programs with Lisata’s operational framework, the combined organization is now well-positioned to navigate the rigorous path to regulatory approval and commercialization, potentially bringing transformative treatments to a patient population that has long struggled with limited therapeutic alternatives.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
